J. Xenotransplantation of SCID/Beige mice with U87 cells and GSDCs provided rise to tumors harboring robust mural cell-associated vascular channels. shRNA restrained VM in tumors and subsequently inhibited tumor development. Collectively, all AMG-Tie2-1 the data demonstrate a central role of Flk-1 in the formation of VM in GBM. This study has shed light on molecular mechanisms mediating tumor aggressiveness and also provided a therapeutic target for patient treatment. gene in mice results in embryonic lethality because of the lack of hematopoietic and endothelial lineage development (20, 21). Once binding with VEGF, Flk-1 undergoes autophosphorylation of tyrosine residues located in an intracellular kinase domain and it subsequently activates multiple intracellular signaling cascades such as focal adhesion kinase (FAK) and MAPK activation, leading to endothelial cell angiogenesis (cell proliferation, migration, and tube formation) (22, 23). Interestingly, previous studies showed that transdifferentiation of embryonic stem cells into vascular endothelial cells and mural cells required expression of Flk-1 (24C26). Rabbit Polyclonal to MED14 However, it is largely unknown whether Flk-1 plays an essential role in the development of VM. Here, AMG-Tie2-1 we take advantage of GBM-derived tumor cell lines capable of developing VM to investigate a role of Flk-1 in the vasculogenesis of GBM. Deciphering the molecular mechanisms will offer considerable value for devising a novel therapeutic regimen targeting nonendothelial vascular proliferation in concert with current anti-angiogenic therapy. EXPERIMENTAL PROCEDURES Cell Culture U87 cells were purchased from the ATCC. GSDCs were established from a tumor sample of a patient with GBM after the study was approved by Baystate Medical Center Institutional Review Board. Briefly, a small fragment of a tumor sample was digested with an enzymatic mixture containing 1.3 mg/ml trypsin (Sigma), 0.67 mg/ml type 1-S hyaluronidase (Sigma), and 0.13 mg/ml kynurenic acid (Sigma). Following extensive washing, cells were resuspended and cultured in DMEM/F-12 supplemented with B27 (Invitrogen) and 20 ng/ml bFGF and EGF for 2 weeks. Then the cells were transferred to a new plate and grown in DMEM supplemented with 10% FBS as the same medium used for U87 cells. GSDCs at passages between 10 and 20 were used for the study. Human microvascular endothelial cells AMG-Tie2-1 (HMVECs) established previously were grown in a medium from the EBM2 kit supplemented with hydrocortisone, EGF, and 10% FBS (Lonza Inc, Allendale, NJ) (27). Tube Formation Tube formation was performed as described previously (28). In brief, cells were plated on growth factor-reduced Matrigel (10 mg/ml, BD Biosciences) overnight, and tubules were fixed with 10% formalin and imaged followed by quantification. Density of tubules was quantified from random selection of three fields under a microscope. Flk-1 Gene Knockdown A PGPU6-GFP-neo shRNA expression vector containing DNA oligonucleotides (21 bp) (GenePharma, Shanghai, China) specifically targeting the C terminus (5-GCTTGGCCCGGGATATTTATA-3) of or the vector with non-sense oligonucleotides as a control was transfected into U87 cells using FuGENE 6. Cells were selected in 800 g/ml G418 starting 48 h after transfection, and GFP expression was monitored to evaluate transfection efficiency. Immunoprecipitation and Immunoblotting Cell lysates were processed as described previously (29). The lysates AMG-Tie2-1 were then incubated with an anti-pY20 antibody (ICN Biomedicals, Aurora, OH) at 4 C overnight followed by incubation with protein A-Sepharose beads at 4 C for 4 h. The immunocomplex was extensively washed, and the samples were run on SDS-PAGE. Then proteins were transferred to a PVDF membrane (VWR, Rockford, IL) and incubated with an anti-Flk-1 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-FAK polyclonal.